Levodopa-carbidopa intestinal gel for advanced Parkinson's ' s disease: Impact of LRRK2 and GBA1 mutations

被引：0

作者：

Thaler, Avner ^{[1
,2
,3
,4
]}

Anis, Saar ^{[1
,5
,6
]}

Ponger, Penina ^{[1
,2
]}

Fay-Karmon, Tsviya ^{[1
,5
,6
,7
]}

Livneh, Vered ^{[1
,2
]}

Faust-Socher, Achinoam ^{[1
,2
]}

Greenbaum, Lior ^{[1
,7
,8
]}

Reiner, Johnathan ^{[1
,10
]}

Hilel, Ariela ^{[2
]}

Shabtai, Hertzel ^{[2
]}

Alcalay, Roy N. ^{[1
,2
,9
]}

Djaldetti, Ruth ^{[1
,10
]}

Hassin-Baer, Sharon ^{[1
,5
,6
,7
]}

Ezra, Adi ^{[2
]}

Mirelman, Anat ^{[1
,3
,4
]}

Giladi, Nir ^{[1
,2
,4
]}

Gurevich, Tanya ^{[1
,2
,4
]}

机构：

[1] Tel Aviv Univ, Fac Med, Tel Aviv, Israel

[2] Tel Aviv Med Ctr & Sch Med, Neurol Inst, Movement Disorder Unit, 6 Weizmann St, IL-64239 Tel Aviv, Israel

[3] Tel Aviv Med Ctr & Sch Med, Neurol Inst, Lab Early Markers Neurodegenerat, Tel Aviv, Israel

[4] Tel Aviv Univ, Sagol Sch Neurosci, Tel Aviv, Israel

[5] Sheba Med Ctr, Dept Neurol, Tel Hashomer, Israel

[6] Sheba Med Ctr, Movement Disorders Inst, Tel Hashomer, Israel

[7] Sheba Med Ctr Tel Hashomer, Danek Gertner Inst Human Genet, Tel Hashomer, Israel

[8] Sheba Med Ctr, Joseph Sagol Neurosci Ctr, Tel Hashomer, Israel

[9] Tel Aviv Med Ctr & Sch Med, Genom Res Lab Neurodegenerat, Tel Aviv, Israel

[10] Rabin Med Ctr, Dept Neurol, Movement Disorders Clin, Petah Tiqwa, Israel

来源：

PARKINSONISM & RELATED DISORDERS | 2024年 / 127卷

关键词：

Parkinson's disease LRRK2; GBA1; Levodopa-carbidopa intestinal gel; LRRK2; GENE;

D O I：

10.1016/j.parkreldis.2024.107115

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Background: Advanced Parkinson's disease (PD) can be treated with Levodopa-Carbidopa Intestinal Gel (LCIG). Objective: To compare descriptive data of LCIG treatment in GBA1-PD and LRRK2-PD. Methods: This multicenter retrospective study compared clinical data obtained from electronic medical records of PD patients treated with LCIG. Patients were grouped based on their genetic status. Results: Fifty-two iPD, 15 LRRK2-PD and 23 GBA1-PD were included in this study. No difference in daily dose of LCIG or levodopa equivalent daily dose were detected. GBA1-PD had significantly shorter disease duration at LCIG initiation (p = 0.01) and experienced more hallucinations (p = 0.03) compared with LRRK2-PD and iPD. LRRK2-PD and iPD had significantly longer duration of LCIG treatment compared with GBA1-PD (p < 0.01). Conclusion: Overall, LCIG treatment was well tolerated in LRRK2-PD and GBA1-PD. GBA1-PD required LCIG earlier in their course of their disease and had higher frequencies of hallucinations during treatment, attesting to a more severe disease course.

引用

页数：4

共 12 条

[1] Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson's disease: a multi-country Delphi-panel approach [J].

Antonini, Angelo ;

Stoessl, A. Jon ;

Kleinman, Leah S. ;

Skalicky, Anne M. ;

Marshall, Thomas S. ;

Sail, Kavita R. ;

Onuk, Koray ;

Odin, Per Lars Anders .

CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (12) :2063-2073

[2] Are patients with GBA-Parkinson disease good candidates for deep brain stimulation? A longitudinal multicentric study on a large Italian cohort [J].

Avenali, Micol ;

Zangaglia, Roberta ;

Cuconato, Giada ;

Palmieri, Ilaria ;

Albanese, Alberto ;

Artusi, Carlo Alberto ;

Bozzali, Marco ;

Calandra-Buonaura, Giovanna ;

Cavallieri, Francesco ;

Cilia, Roberto ;

Cocco, Antoniangela ;

Cogiamanian, Filippo ;

Colucci, Fabiana ;

Cortelli, Pietro ;

Di Fonzo, Alessio ;

Eleopra, Roberto ;

Giannini, Giulia ;

Imarisio, Alberto ;

Imbalzano, Gabriele ;

Ledda, Claudia ;

Lopiano, Leonardo ;

Malaguti, Maria Chiara ;

Mameli, Francesca ;

Minardi, Raffaella ;

Mitrotti, Pierfrancesco ;

Monfrini, Edoardo ;

Spagnolo, Francesca ;

Tassorelli, Cristina ;

Valentino, Francesca ;

Valzania, Franco ;

Pacchetti, Claudio ;

Valente, Enza Maria .

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2024, 95 (04) :309-315

[3] Levodopa-carbidopa intestinal gel infusion (LCIG) in Parkinson disease with genetic mutations [J].

Balestrino, R. ;

Martone, T. ;

Toffoli, M. ;

Montanaro, E. ;

Fabbri, M. ;

Artusi, C. A. ;

Romagnolo, A. ;

Zibetti, M. ;

Rizzone, M. ;

Goldwurm, S. ;

Lopiano, L. ;

Schapira, A. H. V. .

NEUROLOGICAL SCIENCES, 2024, 45 (04) :1489-1497

[4]

BEUTLER E, 1993, AM J HUM GENET, V52, P85

[5] LRRK2 and GBA mutations differentially affect the initial presentation of Parkinson disease [J].

Gan-Or, Z. ;

Bar-Shira, A. ;

Mirelman, A. ;

Gurevich, T. ;

Kedmi, M. ;

Giladi, N. ;

Orr-Urtreger, A. .

NEUROGENETICS, 2010, 11 (01) :121-125

[6] Hierarchical Data-Driven Analysis of Clinical Symptoms Among Patients With Parkinson's Disease [J].

Kozlovski, Tal ;

Mitelpunkt, Alexis ;

Thaler, Avner ;

Gurevich, Tanya ;

Orr-Urtreger, Avi ;

Gana-Weisz, Mali ;

Shachar, Netta ;

Galili, Tal ;

Marcus-Kalish, Mira ;

Bressman, Susan ;

Marder, Karen ;

Giladi, Nir ;

Benjamini, Yoav ;

Mirelman, Anat .

FRONTIERS IN NEUROLOGY, 2019, 10

[7] Translating Evidence to Advanced Parkinson's Disease Patients: A Systematic Review and Meta-Analysis [J].

Nijhuis, Frouke A. P. ;

Esselink, Rianne ;

de Bie, Rob M. A. ;

Groenewoud, Hans ;

Bloem, Bastiaan R. ;

Post, Bart ;

Meinders, Marjan J. .

MOVEMENT DISORDERS, 2021, 36 (06) :1293-1307

[8] Parkinson Disease and Subthalamic Nucleus Deep Brain Stimulation: Cognitive Effects in GBA Mutation Carriers [J].

Pal, Gian ;

Mangone, Graziella ;

Hill, Emily J. ;

Ouyang, Bichun ;

Liu, Yuanqing ;

Lythe, Vanessa ;

Ehrlich, Debra ;

Saunders-Pullman, Rachel ;

Shanker, Vicki ;

Bressman, Susan ;

Alcalay, Roy N. ;

Garcia, Priscilla ;

Marder, Karen S. ;

Aasly, Jan ;

Mouradian, M. Maral ;

Link, Samantha ;

Rosenbaum, Marc ;

Anderson, Sharlet ;

Bernard, Bryan ;

Wilson, Robert ;

Stebbins, Glenn ;

Nichols, William C. ;

Welter, Marie-Laure ;

Sani, Sepehr ;

Afshari, Mitra ;

Verhagen, Leo ;

de Bie, Rob M. A. ;

Foltynie, Tom ;

Hall, Deborah ;

Corvol, Jean-Christophe ;

Goetz, Christopher G. .

ANNALS OF NEUROLOGY, 2022, 91 (03) :424-435

[9] Greater improvement in LRRK2 G2019S patients undergoing Subthalamic Nucleus Deep Brain Stimulation compared to non-mutation carriers [J].

Sayad, Massiva ;

Zouambia, Mohamed ;

Chaouch, Malika ;

Ferrat, Farida ;

Nebbal, Mustapha ;

Bendini, Mohamed ;

Lesage, Suzanne ;

Brice, Alexis ;

Errahmani, Mohamed Brahim ;

Asselah, Boualem .

BMC NEUROSCIENCE, 2016, 17

[10] Mild cognitive impairment among LRRK2 and GBA1 patients with Parkinson's disease [J].

Thaler, Avner ;

Livne, Vered ;

Rubinstein, Einat ;

Omer, Nurit ;

Faust-Socher, Achinoam ;

Cohen, Batsheva ;

Giladi, Nir ;

Shirvan, Julia C. ;

Cedarbaum, Jesse M. ;

Gana-Weisz, Mali ;

Goldstein, Orly ;

Orr-Urtreger, Avi ;

Alcalay, Roy N. ;

Mirelman, Anat .

PARKINSONISM & RELATED DISORDERS, 2024, 123

← 1 2 →